Botulinum Toxin - The Future
Forehead lines is the next indication expected for FDA approval.
Evolus, a new neurotoxin in clinical trials is a joint effort between Alphaeon and the South Korean pharmaceutical firm Daewoo, which should become available in the U.S. next year. The 900 kilodalton (an atomic mass unit) product is similar to Botox for treating glabellar wrinkles, “so there are no real differences in the molecular structure between the two products, but the protein envelope for these two neurotoxins is different,” Dr. Schlessinger says.
Another neurotoxin is in development by Germany-based Croma for glabellar wrinkles.
The company Revance has been investigating for several years now a longer-lasting neurotoxin via a unique carrier for the toxin. The firm also has conducted some studies of topical application of the toxin for indications ranging from crow’s feet to hyperhidrosis (excessive sweating).
Meanwhile, Botox has licensed a toxin from Korean-based Medytox.
“As indications expand and are able to be promoted by the individual companies, these indications will become more popular,” Dr. Schlessinger says.
Disclosure: Dr. Schlessinger reports being an investor in Alphaeon, as well as a shareholder in Allergan and Revance.